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Review
Human variability underlies differences in the 
degrees and ways in which people respond 
to environ mental chemi cals, and address­
ing these differences is a key consideration 
in human health risk assessments for chemi­
cals [Guyton et al. 2009; Hattis et al. 2002; 
National Research Council (NRC) 2009]. 
A large array of possible health outcomes is 
of concern for such assessments, and many 
sources of variation can influence the sever­
ity and frequency of the adverse effects at dif­
ferent exposure levels. These sources may be 
intrinsic (e.g., heritable traits, life stage, aging), 
or extrinsic, exogenous, and acquired (e.g., 
background health conditions, co­occurring 
chemi cal exposures, food and nutrition status, 
psychosocial stressors). Interactions between 
inherent and extrinsic factors create the large 
range of biological variation exhibited in 
response to a chemi cal exposure (NRC 2009). 
Given that biological variability in susceptibil­
ity is context­ dependent, so too is the extent to 
which it needs to be described and quantified 
to inform any particular environ mental deci­
sion. The salience of variability information for 
specific choices is affected by the range of avail­
able risk management options; the regulatory 
authority; the available time, resources, and 
expertise to collect data and conduct analyses; 
and stakeholder concerns.
Over the past decade, efforts to systemati­
cally “map” human variability have expanded 
dramatically, focusing mainly on genetic 
variation (Schadt and Björkegren 2012). In 
addition to genetic differences, omics stud­
ies have examined the impact of epigenetic, 
transcriptomic, proteomic, and metabolo­
mic variation on disease susceptibility, 
prognosis, or options for pharmacotherapy 
(Chen et al. 2008; Emilsson et al. 2008; Illig 
et al. 2010; Manolio 2010; Schadt 2009). 
Tailored chemotherapy treatment based on 
patient (Phillips and Mallal 2010) or tumor 
(La Thangue and Kerr 2011) genetics is an 
example of a significant success in applying 
such discoveries; however, for many diseases, 
the substantial nongenetic variation in disease 
or treatment outcomes has limited their util­
ity. Thus, the characterization of the broad 
set of environ mental factors, including those 
related to chemi cal exposures, that may con­
tribute to disease is directly relevant to both 
personal ized medicine and environ mental 
health protection (Khoury et al. 2011).
In this review, we explore how next­
 generation (“NexGen”) human health risk 
assessments of chemi cals might take advantage 
of novel data to better characterize and quan­
tify variability in susceptibility, by using and 
expanding upon current analytical methods. 
We begin by describing biological variabil­
ity through the conceptual framework of the 
source­to­outcome continuum. Next, the util­
ity of that framework is illustrated in a review 
of current approaches to describing variability 
in susceptibility in human health risk assess­
ments. Then, emerging data streams that may 
be informative in characterizing human vari­
ability in susceptibility are described. Finally, 
we consider the opportunities, challenges 
and methods for using emerging data to help 
assess inter individual variability in responses 
to environ mental  chemi cals across different 
decision contexts.
Susceptibility as a Function 
of the Source-to-Outcome 
Continuum and Biological 
Variability
The “source­to­outcome continuum” [U.S. 
Environmental Protection Agency (EPA) 
2007; NRC 2007] is a conceptual frame­
work for human health risk assessment of 
environ mental chemi cals in which changes in 
the sources of chemi cals in the environment 
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Background: Characterizing variability in the extent and nature of responses to environ mental 
exposures is a critical aspect of human health risk assessment.
Objective: Our goal was to explore how next-generation human health risk assessments may 
better characterize variability in the context of the conceptual framework for the source-to-outcome 
 continuum.
Methods: This review was informed by a National Research Council workshop titled “Biological 
Factors that Underlie Individual Susceptibility to Environmental Stressors and Their Implications 
for Decision-Making.” We considered current experimental and in silico approaches, and emerg-
ing data streams (such as genetically defined human cells lines, genetically diverse rodent models, 
human omic profiling, and genome-wide association studies) that are providing new types of infor-
mation and models relevant for assessing inter individual variability for application to human health 
risk assessments of environ mental chemi cals.
Discussion: One challenge for characterizing variability is the wide range of sources of inherent 
biological variability (e.g., genetic and epigenetic variants) among individuals. A second challenge is 
that each particular pair of health outcomes and chemi cal exposures involves combinations of these 
sources, which may be further compounded by extrinsic factors (e.g., diet, psychosocial stressors, 
other exogenous chemi cal exposures). A third challenge is that different decision contexts present 
distinct needs regarding the identification—and extent of characterization—of inter individual varia-
bility in the human population.
Conclusions: Despite these inherent challenges, opportunities exist to incorporate evidence from 
emerging data streams for addressing inter individual variability in a range of decision-making contexts.
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are further propagated within the individual 
through a series of biological and physiologi­
cal steps that may ultimately manifest as an 
adverse health outcome (Figure 1):
Source/media concentrations•	  are measures 
of the chemi cal, which may change under 
specific risk management options being con­
sidered. A given risk management decision 
may differentially affect media concentra­
tions depending on local conditions.
External doses•	  are measures of exposure (e.g., 
concentration in air × breathing rate per body 
weight) to or intake (e.g., amount ingested 
per body weight) of environ mental chemi cals, 
and are related to source/media concentra­
tions by exposure pathways. Sources of vari­
ability that may confer susceptibility include 
differences in behaviors, such as breathing 
rates, water consumption, and dietary habits 
(e.g., the amount of fish consumed), and, 
in an occupational context, use of personal 
 protective equipment.
Internal doses•	  are the amounts/concentrations 
of environ mental chemi cals or their metabo­
lites at the target site(s) of interaction with 
biological molecules, and are related to exter­
nal doses by pharmaco kinetic (PK) processes. 
Susceptibility may arise from differences in 
compartment sizes and composition (e.g., fat 
concentration in plasma, which rises during 
pregnancy) (Roy et al. 1994), as well as dif­
ferences in the rates of uptake (e.g., fraction 
absorbed from diet or air), metabolism, elim­
ination, and transport to sites of action (e.g., 
the blood–brain barrier). Such differences 
may be due, for example, to genetics (e.g., 
via poly morphisms in metabolic enzymes, 
uptake and efflux transporters), other chemi­
cal exposures (via meta bolic enzyme induc­
tion and inhibition), and preexisting health 
conditions and life stage (e.g., via metabolism 
and mobilization from tissue storage).
Biological responses•	  are measures of biological 
state (e.g., the concentration of gluta thione) 
altered by interactions with environ mental 
chemi cals or their metabolites, and are related 
to internal doses by pharmaco dynamic (PD) 
processes. Variation leading to differential 
susceptibility can stem from differences in 
transport systems, receptors and/or proteins 
in other toxicity pathways, as well as repair 
capacity (of, for example, DNA), which in 
turn are affected by intrinsic and extrinsic 
factors such as genetics and life stage.
Physiological/health status•	  reflects the overall 
state, structure, or function of the organ­
ism and is related to biological responses 
through systems dynamics, the underlying 
physiological status of the host to which 
the chemi cal­specific perturbation is added. 
Examples include maintenance and adapta­
tion processes (associated with preexisting 
health conditions, sex hormone levels, for 
example), and the accumulation of dam­
age events from past exposures (e.g., loss 
of alveolar septa from past cigarette smoke 
Figure 1. Framework illustrating how susceptibility arises from variability. Multiple types of biological variability intersect with the source-to-outcome continuum, 
either by modifying how changes to source/media concentrations propagate through to health outcomes or by modifying the baseline conditions along the con-
tinuum. The aggregate result of all these modifications is variability in how a risk management decision impacts individual health outcomes. The parame ters and 
initial conditions along the source-to-outcome continuum serve as indicators of differential susceptibility, some of which are more or less influential to the overall 
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exposure). Variation in these can confer 
susceptibility by altering the likelihood of 
progression from normal function to mild 
perturbations, early disease, and late disease. 
Systems dynamics describes the propaga­
tion of biological perturbations regardless 
of whether they are due to chemi cal expo­
sure, thus distinguishing it from pharmaco­
dynamics, which describes how chemi cal 
exposure causes biological  perturbations.
Figure 2 illustrates the distinct effects of 
different sources of variability on external 
dose, internal dose, or biological response. The 
first category of biological variability is indi­
cated by differences in the parame ters gov­
erning the relationship of one measureable 
quantity to the next (e.g., external to internal 
dose, and internal dose to biological response) 
(Figure 2A,B). In addition, there may be bio­
logical variability in the initial conditions for 
each measureable quantity, as well as the con­
tribution from the source of environ mental 
chemi cal exposure under consideration for 
risk management (Figure 2C,D). For exam­
ple, increases in background exposure to the 
same or a different chemi cal(s) may result 
in saturation of metabolic activation and/or 
clearance processes, or temporary depletion 
of cofactors involved in detoxification, such 
as glutathione, resulting in either attenuation 
or amplification of the effect of additional 
increments of chemi cal exposure on internal 
dose (Figure 2C). Nonetheless, a biological 
response with a low background level may be 
much less altered by additional exposure than 
one with a high background because of to the 
cooperativity associated with a relatively higher 
baseline internal dose (Figure 2D).
Current Approaches 
to Addressing Variable 
Susceptibility
Variability for assumed threshold­like dose–
response relationships is currently addressed 
by applying an “uncertainty” or “adjustment” 
factor (U.S. EPA 2011). The factor to account 
for inter individual variability in human popu­
lation has typically been 1, 3, or 10. In some 
cases, the factor is further divided to separately 
account for variation in PK and PD (U.S. 
EPA 2011; International Programme for 
Chemical Safety 2001). In this context, PD 
has included both PD and systems dynamics 
processes described above and in Figure 1. 
Data permitting, the PK component can 
be addressed through physiologically based 
pharmaco kinetic (PBPK) modeling, in which 
case a factor addressing only PD is applied 
(U.S. EPA 2011). Occasionally, exposure–
effect observations are available for particularly 
susceptible human populations, such as with 
ozone and persons with asthma (U.S. EPA 
2006), or those sensitive to chronic beryllium 
disease (U.S. EPA 1998), which allows for a 
data­driven estimation of the likely impact of 
inter individual variability on human health 
risk assessments.
For presumed nonthreshold cancer end 
points, inter individual variability is not cur­
rently addressed when risk is estimated from 
animal studies, with the exception that for 
mutagenic compounds exposures occurring 
early in life are weighted more heavily (by a fac­
tor of 10 between birth and 2 years of age, and 
a factor of 3 between 2 and 16 years of age). 
Cancer risk for susceptible populations, such as 
smokers who have been exposed to radon, may 
be calculated in addition to that for a general 
population (U.S. EPA 2003). Alternatively, 
adjustments may be made to address suscep­
tible subgroups, such as the sex­specific effects 
of 1,3­butadiene (U.S. EPA 2002). There have 
been calls to formally account for variability in 
cancer dose response (NRC 2009).
Over the past 30 years, several strategies 
to characterize (predominantly PK) variability 
combining mathematical models and statistical 
distributions have developed in parallel. The 
first strategy, mostly used for data­rich pharma­
ceuticals, couples empirical PK models and 
multilevel (random effect) statistical models to 
extract a posteriori estimates of variability from 
clinical data on patients or volunteers. This 
“population PK” approach (Beal and Sheiner 
1982) seeks to measure variability and to dis­
cover its determinants. The second, the “pre­
dictive PK,” approach takes advantage of the 
predictive capacity of mechanistic models and 
assigns a priori distributions to their parame ters 
(e.g., blood flows, organ volumes). The parame­
ters having biological meaning can be observed 
through independent experiments, clinical 
measurements, or surveillance. Table 1 lists 
some examples of data sources for developing 
a priori parame ter distributions. Monte Carlo 
simulations are used to propagate the distribu­
tions from model parame ters to model pre­
dictions (Portier and Kaplan 1989; Spear and 
Bois 1994). A third approach, the “Bayesian 
PBPK” approach, offers a synthesis of the other 
two, applying mechanism­ or chemi cal­specific 
parame ter variability data from a variety of 
independent sources while using population 
observations of relevant biomarkers of internal 
exposure and effect to further inform parame­
ter variability (Allen et al. 2007; Bernillon 
and Bois 2000; Hack 2006). Parameter cova­
riance can be modeled by multivariate prior 
distributions (Burmaster and Murray 1998) 
or joint posterior distributions obtained by 
Bayesian multi level modeling (Bois et al. 1990; 
Wakefield 1996). A Bayesian PBPK model­
based analysis of the population toxicokinetics 
of trichloro ethylene (TCE) and its metabolites 
in mice, rats, and humans provides a practical 
example of how a syste matic method of simul­
taneously estimating model parame ters and 
characterizing their uncertainty and variability 
can be applied to a large database of studies on 
a chemi cal with complex toxicokinetics (Chiu 
et al. 2009).
PBPK models have been often used to 
assess variability on the basis of prior parame­
ter distributions obtained from in vitro experi­
ments or the physiological literature (Bois 
et al. 2010; Jamei et al. 2009) and can include 
genetic information regarding variability. 
For example, PBPK models can inform the 
Figure 2. Effects of variability in PK (A), PD (B), background/coexposures (C), and endogenous concentra-
tions (D). In (A) and (B), individuals differ in PK or PD parame ters. In (C) and (D), individuals have different 
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implications of polymorphisms in metabolism 
genes (Johanson et al. 1999). The effects of 
such polymorphisms on PK of environ mental 
toxicants and drugs have been the subject of 
many empirical studies (reviewed by Ginsberg 
et al. 2009c, 2010). These polymorphisms are 
of particular concern for xenobiotics whose 
metabolic fate or mechanism(s) of action is 
controlled by a particular enzyme (Ginsberg 
et al. 2010), and in such cases genetic variabil­
ity can profoundly influence enzyme function 
with implications for internal dose (Figure 1). 
However, because enzymatic pathways with 
overlapping or redundant function and other 
pharmaco kinetic factors (e.g., blood flow 
limitation) can also influence metabolic fate 
(Kedderis 1997), PBPK models are needed to 
evaluate the implication of genetic polymor­
phisms in metabolizing enzymes in human 
health risk assessment (Ginsberg et al. 2010).
The situation is somewhat different for PD 
and systems toxicology models. The biologically 
based dose–response models describe apical or 
intermediate end point responses as a function 
of PK­defined internal doses (Crump et al. 
2010). However, models designed purely from 
our understanding of the disease process, such 
as the role of cytotoxicity and regenera tive pro­
liferation in carcinogenesis (Luke et al. 2010b), 
or the effect of dietary iodide and thyroid hor­
mones on the hypothalamic– pituitary– thyroid 
axis (McLanahan et al. 2008), require further 
development to reliably predict an adverse out­
come from tissue exposure (the last two arrows 
in Figure 1), or its variability. Understanding 
a disease process at the pathway level (i.e., 
PD and systems dynamics components of the 
source­to­ outcome continuum) is in itself not 
sufficient to define reliable and informative 
mechanistic models because of great model sen­
sitivity to uncertain inputs. Most such models 
are based on equations derived from the classi­
cal receptor theory (Csajka and Verotta 2006) 
and focus on PD rather than system dynam­
ics elements of the disease process and do not 
attempt to model the full process from tissue 
exposure to disease outcome.
Emerging Data Streams 
on Biological Variability
Experimental population­based paradigms 
to address intrinsic variability in response to 
exposure comprise multiple levels of biological 
organization, from molecules to whole bodies. 
Published examples, reviewed by Rusyn et al. 
(2010), include animal models and large­
scale in vitro screening platforms to study 
population­ based genetic determinants. Those 
studies have also aided in the identification of 
genetic susceptibility factors that underlie toxi­
city phenotypes. Complementary to these are 
genome­wide (Hutter et al. 2012) and expo­
sure­wide (Patel et al. 2010) association stud­
ies for assessing human population varia bility.
Experimental in vitro data on genetic 
variability. Human cell lines obtained from 
genetically diverse subjects and multiple popu­
lations (Durbin et al. 2010) hold the promise 
of providing data for assessing genetic deter­
minants of different components of toxic 
response. Many recent studies have used 
human lymphoblastoid cell lines, represen­
tative of the genetic diversity in populations 
of European, African, Asian, and North and 
South American ancestry, to quantify inter­
individual and interpopulation variability in 
response to drugs (Welsh et al. 2009). Dozens 
of studies published in the past 5 years have 
profiled the cytotoxicity of single to as many 
as 30 drugs (mostly chemotherapeutics) in 
hundreds of cell lines. Diverse applications 
for such a population­based cell model has 
been suggested. Drug class–specific signatures 
of cytotoxicity, which could indicate possi­
ble shared mechanisms, have been identified 
and replicated in both cell lines from different 
populations and for additional compounds 
(Watson et al. 2011). Furthermore, such stud­
ies may potentially inform the prioritiza tion of 
chemotherapeutic drugs with a sizable genetic 
response component for future investigation 
(Peters et al. 2011) and assist in identifying 
germline predictors of cancer treatment out­
comes (Huang et al. 2011).
The utility of such in vitro models to 
toxicol ogy, especially for exploring the extent 
and nature of genetic components of inter­
individual variability in PD and systems 
dynamics, was recently demonstrated (Lock 
et al. 2012; O’Shea et al. 2011). Quantitative 
high­throughput screening (qHTS) pro­
duced robust and reproducible data on intra­
cellular levels of adenosine triphosphate and 
caspase­3/7 activity (i.e., biological response) 
indica tive of general cytotoxicity and activa­
tion of apoptosis (i.e., physiological status), 
with utility for variability assessment as fol­
lows. First, standardized and high­quality 
concentration–response profiling, with repro­
ducibility confirmed by comparison with pre­
vious experiments, enables prioritization of 
chemi cals based on inter individual variability 
in cytotoxicity. Second, genome­wide associa­
tion analysis of cytotoxicity phenotypes allows 
exploration of the potential genetic determi­
nants of that variability. Finally, the highly 
significant associations between basal gene 
expression variability and chemi cal­induced 
toxicity suggest plausible mode­of­action 
hypotheses for follow­up analyses.
Several extensions of these studies can be 
envisioned to advance the identification of 
determinants of genetic susceptibility and vari­
ability in toxic response. Opportunities include 
the testing of additional, and more diverse, 
chemi cals (including major metabolites) and 
concentrations (to account for lower meta­
bolic capacity of these cells). Other specific end 
points could also be assessed. Further, these 
studies could be expanded to include larger 
panels of lymphoblasts and other cell types 
from genetically and geographically diverse 
populations. Development of related assay sys­
tems to monitor differences in susceptibility to 
perturbation of communication between cells 
(e.g., neurotransmission or differentiation sig­
nals) could address other aspects of variability 
not present in cultures comprising only one 
kind of cell. The development and use of these 
and other types of in vitro assays would be fur­
ther informed by quantitative comparisons of 
the PD inter individual variability measured 
in vitro with observable human pharmaco­
dynamics variability in vivo. Candidate chemi­
cals for this comparison would be selected 
environ mental toxicants (such as ozone) and 
pharmaceuticals that have been tested for 
responses in appreciable numbers of human 
subjects at different known exposure levels. The 
extent of inter individual variability in response 
Table 1. Examples of data sources for modeling PK and PD variability.
Example References
Variability in human phase I and phase II metabolism and renal excretion, 
including in different age groups–neonates, children, and the elderly
Dorne 2010; Ginsberg et al. 2002, 2004; 
Hattis et al. 2003
Compilations of genetic polymorphisms of specific metabolic enzyme 
activities:
Paraoxonase Ginsberg et al. 2009a
N-Acetyltransferase 1 and 2 Bois et al. 1995; Walker et al. 2009
Glutathione transferases Ginsberg et al. 2009b
CYP2D6 (cytochrome P450 2D6) Neafsey et al. 2009b
CYP2E1 (cytochrome P450 2E1) Neafsey et al. 2009a
ALDH2 (acetaldehyde dehydrogenase 2) Ginsberg et al. 2009c
Human biomonitoring observations of inter individual differences in 
biomarkers of exposure (e.g., chemi cal-protein adducts) or in levels of 
parent/metabolite
Bois et al. 1996
Variability in physiological parame ters for older adults: bodymass, 
surface area, body mass index, health status
Thompson et al. 2009
Indicators of PD variability
Human DNA repair enzyme XRCC1 Ginsberg et al. 2011
Human host defense enzymes Ginsberg et al. 2010
Lung function response to particulate matter Hattis et al. 2001
Susceptibility to infectious organisms Hattis 1997
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that was observed for different chemi cals in 
in vitro assays could also be compared with 
previously collected sets of in vivo human PD 
variability data (Hattis et al. 2002).
Experimental in vivo data. Several proof­
of­concept studies that utilized a “mouse model 
of the human population” have demon strated 
the potential for translation to clinical appli­
cations and for addressing both PK and PD 
components of variability (Guo et al. 2006, 
2007; Harrill et al. 2009b; Kleeberger et al. 
1997; Prows et al. 1997). For example, the 
extent and nature of TCE metabolism is an 
important consideration in relating adverse 
health effects in rodents to humans. Bradford 
et al. (2011) measured variability in PK for 
TCE using a panel of inbred mouse strains, 
revealing marked differences among indi­
vidual mice (e.g., a greater than 4­fold differ­
ence in peak serum concentrations of TCE 
metabolites). These experimental data on intra­
species differences in TCE metabolism may be 
used to calibrate the variability in outputs of 
PBPK models, and thus inform quantitative 
assessment of variability in TCE metabolism 
across species.
With regard to PD variability, genetically 
diverse mouse strains can be used to under­
stand and predict adverse toxicity in hetero­
geneous human populations. For example, 
Harrill et al. (2009a) evaluated the role 
of genetic factors in susceptibility to 
acetaminophen­ induced liver injury in a panel 
of inbred mouse strains and two cohorts of 
human volunteers. The authors identified 
genes associated with differential susceptibility 
to toxicity in a preclinical phase. This finding 
has the potential to focus further toxico­
genetics research, overcome the challenges of 
studies in small human cohorts, and shorten 
the validation period. The data acquired 
with this model may be used in analyses of 
individual risk to toxicants. Furthermore, 
when combined with omics data collected on 
an exposed population of individual strains, 
it may be possible to explore underlying 
genotype­ dependent and ­independent 
toxicity pathways involved in PD response 
(Bradford et al. 2011; Harrill et al. 2009a).
Experiments such as these afford the 
opportunity to quantitatively understand the 
interplay between genetics, PD, and systems 
dynamics. In addition, genetically defined 
mouse models may be used to supplement 
the limited data from human studies to not 
only discover the genetic determinants of 
susceptibility and understand the molecular 
underpinnings of toxicity (Harrill et al. 
2009a; Koturbash et al. 2011) but also to 
develop descriptions of variability for use in 
dose– response and mechanistic evaluation 
components of human health risk assessments.
Such rodent systems can also be used to 
assess the role of epigenetics, as well as its 
potential interplay with the genetic back­
ground, in susceptibility. For example, 
Koturbash et al. (2011) demonstrated that 
interstrain differences in susceptibility to 1,3­
butadiene–induced genotoxicity may be due 
to strain­specific epigenetic events that are also 
part of a PD response.
Practical use of this type of experimental 
information is possible mainly when the mech­
anistic pathways to human adverse responses 
are better established. More general application 
will also depend on the development of suites 
of rodent models that more fully represent 
human diversity in both genetics and other 
factors, such as age (Hamade et al. 2010). Such 
studies can, in turn, provide important insights 
concerning the identity and extent of sources 
of variability that may arise in the source­to­
outcome continuum for a given chemi cal class, 
physiologic state, or adverse response.
Human clinical and observational data. 
Genome­wide association studies (GWAS) 
with disease severity as the phenotypic trait 
are used to associate genetic loci with risk for 
complex diseases (Rosenberg et al. 2010). 
Even though GWAS approaches have uncov­
ered numerous genomic loci that may affect 
the risk of human disease (Manolio 2010), 
the identified variants explain only a small 
proportion of the heritability of most complex 
diseases (Manolio et al. 2009). Some have sug­
gested that unexplained heritability could be 
partly due to gene × environment interactions, 
or complex pathways involving multiple genes 
and exposures (Schadt and Björkegren 2012).
The GWAS concept is now being applied 
to identify additional genotype­dependent 
metabolic phenotypes and to gain insight 
into nongenetic factors that contribute to the 
effects of xenobiotics on system dynamics. In 
animal studies, metabolic phenotype­related 
quantitative trait loci were shown to be use­
ful in understanding genome ×  phenotype 
relationships and how extended genome 
(microbiome) perturbations may affect dis­
ease processes through transgenomic effects 
(Dumas et al. 2007). In a series of human 
studies (Gieger et al. 2008; Illig et al. 2010; 
Suhre et al. 2011), serum collected from two 
large European cohorts (2,820 individuals in 
total) was analyzed with nontargeted metabo­
lomics, focusing on endogenous metabolites 
and covering 60 biochemi cal pathways. Ratios 
of metabolites to parent chemi cal concentra­
tions served as surrogates for enzymatic rate 
constants. Thirty­seven genes were associated 
with blood metabolite concentrations and, in 
some cases, explained a substantial fraction 
of the variance. Endogenous and xenobiotic 
metabolites (mostly of drugs) were studied.
Clinical (Brown et al. 2008; Hernandez 
et al. 2010) and epidemiological (Jia et al. 
2011; Wood et al. 2010) studies of acute 
and chronic effects of ambient air exposures 
have long had important roles in quantifying 
human variability in the risks of exposures 
to widespread toxicants such as ozone and 
airborne particulates. The addition of GWAS 
to these established tools has the potential 
to widen the capability for quantification of 
effects on susceptibility of many individual 
genotypic variants that individually have rela­
tively modest effects (Holloway et al. 2012). 
Establishing the roles of individual pathways 
in affecting susceptibility via genetic analysis, 
in turn, has the potential to advance the assess­
ment of effects of other exposures during life 
that also affect the same pathways. Elucidating 
these determinants for prominent toxicants, 
however, requires a very considerable research 
effort. Nonetheless, this research paradigm 
provides opportunities to explore variability in 
adverse responses that is due to physiological 
states for which in vitro and experimental ani­
mal models are lacking.
Variability in human response to an agent 
stems in part from differences in the under­
lying exposures that contribute to a given dis­
ease response prevalence within the population. 
A person’s internal “chemi cal environment” 
may be as important for possible disease asso­
ciations as exposures to the variety of chemi cals 
in the external environment. Under this “expo­
some” concept (Wild 2005), exposures include 
environ mental agents and internally generated 
toxicants produced by the gut flora, inflamma­
tion, oxidative stress, lipid peroxidation, infec­
tions, and other natural biological processes 
(Rappaport and Smith 2010).
Advances in in Silico Methods 
to Address Human Variability
Modeling of variability is expected to be 
needed for both data­rich and ­sparse chemi­
cals. Recent advances in software, publicly 
available data and ongoing computational 
activities in biomedical research should facili­
tate the development and use of the results of 
this type of modeling.
Modeling the PK dimension of human 
variability. Commercial software prod­
ucts [e.g., by Simcyp (http://www.simcyp.
com), Bayer Technology (http://www.pksim.
com)] are available to explicitly address vari­
ability for pharmaceutical or human health 
risk assessment applications to, for example, 
adjust dosing for different target patient popu­
lations (Jamei et al. 2009; Willmann et al. 
2007). Several of these offer generic PBPK 
models, applicable to “any” substance; how­
ever, their substance­specific parame ters have 
to be obtained from in vitro experiments 
(particularly on metabolism) or quantitative 
structure–property relationships. The variabil­
ity of subject­specific physiological parame ters 
can be informed by compiled databases (see 
above) and literature searches (Bois et al. 2010; 
Ginsberg et al. 2009c), and could include 
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adjustments or protocols to address limitations 
in data availability. Quantitative structure– 
property relationship models or in vitro data 
can also be used to derive substance­specific 
parame ters. These models are being applied in 
an exploratory fashion in in vitro–based assess­
ments (Judson et al. 2011; Rotroff et al. 2010).
Using a Bayesian multilevel population 
approach, some of the key parame ters of 
these generic models could be calibrated by 
integrating human observational data with data 
from lower levels of biological organization. 
This presents a computational challenge on 
a chemi cal­specific basis, because those 
models are neither particularly parsimonious 
nor quickly evaluated. Yet an extensive 
calibration of a complex generic model for a 
selected number of data­rich environ mental 
or pharma ceutical chemi cals could be used 
as support to develop generic approaches for 
PK varia bility treatment in human health risk 
assessment. For example, generalizations could 
be made about the extent to which particular 
enzymes may contribute to overall human PK. 
Extensions of the approach of Hattis et al. 
(2002) can also be developed to construct 
“bottom up” quantitative descriptions of PK 
variability that can be applied as defaults across 
classes of chemi cals.
Modeling the PD dimension of human 
variability. Semi­empirical PD models can 
include observed biomarkers of susceptibil­
ity as covariates. Such models are increas­
ingly applied in predictive toxicity and 
human health risk assessment. Environmental 
epidemiol ogy also routinely models quantal 
types of biomarker data in logistic regressions. 
Harmonizing the tools and models of toxico­
logical risk assessment with those of epidemio­
logical risk assessment, and reconciling their 
data and results, should facilitate the develop­
ment of better approaches for background 
and variability descriptions in NexGen human 
health risk assessments.
Integrating PK and PD into a systems 
biology framework. The link between toxicity 
pathway and “normal cell physiology” models 
of systems biology could also be further devel­
oped and used as the basis to explore poten­
tial ranges of human variability. The potential 
of publicly accessible and curated biomodel 
and database repositories will be increasingly 
exploited as familiarity increases in the risk 
assessment and risk management communi­
ties. Importantly, systems biology models can 
describe background biological processes and 
the impact of their perturbation and provide a 
framework for exploring human variability and 
identifying susceptible populations for targeted 
assessment and management efforts. Although 
they come at the price of tremendous complex­
ity, their development can leverage the consid­
erable ongoing effort by the biomedical and 
pharmaceutical research community to support 
applications other than toxicant risk evaluation. 
Further, because of these large­scale efforts, the 
necessity of sharing and standardization is well 
understood in the United States. The systems 
biology markup language (Hucka et al. 2003), 
for example, is a high­level language developed 
explicitly to provide a common intermediate 
format for representing and exchanging sys­
tems biology models. Predictive toxicology will 
benefit from these developments.
The frontier for both PK and PD is in the 
integration of the rapidly growing informa­
tion about metabolic networks, receptors, and 
their regulation with toxicity pathways. The 
models so far most amenable to quantitative 
predictions are differential equation models. 
PBPK models will likely be merged with 
systems biology and virtual human models. 
The boundary between PK and PD actually 
tends to blur as metabolism becomes more 
and more integrated into detailed models of 
toxicity pathways when, for example, model­
ing enzymatic induction by xenobiotics (Bois 
2010; Luke et al. 2010a). The variability of the 
different components of those models will be 
directly informed by time series of genomic, 
proteomic, metabolomic data on the chemi­
cal species considered. This may provide 
a framework for assessing the variability in 
susceptibility to chemi cally induced effects 
as influenced by possible metabolic interac­
tions as well as preexisting disease. In time 
this may facilitate computing the impact of, 
for example, single nucleotide polymorphisms 
on the reaction rates of enzymes and recep­
tors and translating these calculations to esti­
mates of human variability (Mortensen and 
Euling 2011). Ongoing work on simula tions 
of enzymatic reactions or receptor binding at 
the atomic level (e.g., the potassium channel 
pore) shows the way forward for predicting 
fundamental reaction rates by physical chem­
istry approaches. Prediction of the quantitative 
impact of sequence or amino­acid variation on 
the function of the reactive species involved in 
systems biology models is coming within reach 
(Giorgino et al. 2010; Sadiq et al. 2010).
Biologically based PD models, such as the 
systems biology models of response networks 
(Schuster 2008), models of toxicity pathway 
perturbations, and biologically based dose–
response models proposed to link biochemi cal 
responses to apical effects, clearly hold promise 
(Csajka and Verotta 2006; Jonsson et al. 2007; 
Nong et al. 2008) but face challenges similar 
to those that hampered the use of biologically 
based cancer models (Bois and Compton­
Quintana 1992; Chiu et al. 2010). To explore 
the extent of human variability in response to 
toxicant and stressor exposures, the various 
steps in the relevant causal path need to be 
modeled quantitatively and on a population 
basis. A problem is that the quantitative link­
ing of omics biomarkers to risk is missing. For 
many markers (e.g., of apoptosis, cell divi­
sion), the linkage to risk is highly uncertain 
(Woodruff et al. 2008), so the ranges of pos­
sible variability may be very large. Further, 
the ability to reinforce information by linking 
with the impact of injury on multiple targets 
is also limited because such links are generally 
not well understood.
Implications for NexGen Human 
Health Risk Assessments
Multiple “tiers” of human health risk assess­
ment needs, requiring different levels of 
precision, can be envisioned. These include 
screening­level analyses of multiple chemi cals 
to inform the prioritization of management 
and enforcement actions across communities, 
ensuring protection across the population to 
widespread exposure to legacy contaminants, 
or identifying subpopulations for which differ­
ing risk management options might be applied.
In the lowest (simplest) tier of assessments, 
evaluations are expected to primarily rely on 
the results of high­ and medium­ throughput 
in vitro screening tests in mostly human cell 
lines, as well as complementary in silico predic­
tive methods. The Tox21 collaboration (Collins 
et al. 2008) is leading the field in exploring how 
a broad spectrum of in vitro assays, many in 
qHTS format, can be used to screen thousands 
of environ mental chemi cals for their potential 
to disturb biological pathways that may result 
in human disease (Xia et al. 2008). Such data 
on toxicologically relevant in vitro end points 
can be used as toxicity­ based triggers to assist 
in decision making (Reif et al. 2010), as predic­
tive surrogates for in vivo toxicity (Martin et al. 
2010; Zhu et al. 2008), to generate testable 
hypotheses on the mechanisms of toxicity (Xia 
et al. 2009), and to develop screening assays 
based on pathway perturbations. The extent of 
inter individual variability in toxic response to 
be estimated from these types of assays can be 
informed by empirical data and PK/PD models 
that address multiple factors in the source­ to­
 outcome continuum as described in Figure 1. 
The genomic component of variability may 
be partially informed by test data from geneti­
cally diverse but well­defined human cell lines, 
such as from the HapMap (http://hapmap.
ncbi.nlm.nih.gov/) and 1000 Genomes (http://
www.1000genomes.org/) projects. For exam­
ple, emerging data based on standardized and 
high­quality concentration– response profiling 
can help inform characterizations of the extent 
of inter individual variability in cytotoxicity. 
When chemi cal­specific estimates are lack­
ing, the range of inter individual variability for 
structurally related compounds may be infor­
mative, in a read­across approach. Quantitative 
data characterizing the range in response (e.g., 
size and variance) may be integrated with 
probabilistic default distribu tions addressing 
the remaining key sources of inter individual 
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variability. Quantitative estimates of PK vari­
ability would be also incorporated. In addition, 
factors such as life stage and background expo­
sures may be particularly important consider­
ations for approaches accounting for baseline 
differences in the spectrum of the “chemi cal 
environment” (Rappaport and Smith 2010), 
in interpreting results from the omics assays, 
and in evaluating the potential contributions of 
non genetic variability factors.
At these lower tiers, a probability distri­
bution may best acknowledge the many uncer­
tainties involved in making inferences with 
limited data. Systematic analyses of chemi cal 
sets will be needed to refine distributions for 
the chemi cal­specific and general case. For 
instance, external comparisons of in vitro mea­
sures based on genetic variability in pharmaco­
dynamics to in vivo observations may inform 
the choice of distribution used for a particular 
chemi cal or chemi cal category. Standard cate­
gories, comprising different size and variance 
distributions for multiple variability factors 
that can then be applied to other chemi cals, 
may emerge from these analy ses. The ranking 
and grouping of chemi cals for the applica­
tion of these distributions may be based on 
structural class, the relative extent of observed 
varia bility, a common determinant of vari­
ability (e.g., as identified in GWAS analysis of 
cyto toxicity pheno types), or other factors (e.g., 
likelihood of coexposures or confounders). 
Compounds demonstrated or predicted to 
have highly variable toxic responses may also 
be given a higher priority for further study, in 
combination with chemi cal and other expected 
modifiers of susceptibility.
At higher tiers of NexGen human health 
risk assessments, animal and in some cases 
human data are available for evaluating dose–
response relationships, major pathways for 
some of the critical toxicities for risk assess­
ment can be reasonably well understood, and 
some in vivo human data relevant to those 
pathways may be available. For some chemi­
cals, sensitive populations may have been iden­
tified and studied using omics technologies. In 
the case of ozone, for example, gene expression 
data and genomic markers may be collected 
on individuals of high and average sensitivity. 
Toxicity pathways exhibited in cultured air­
way epithelial cells exposed to ozone may also 
be compared with those in humans exposed 
in vivo to ozone. Such data will aid a better 
characterization of the dose–time– response 
severity relationships at low doses. In other 
cases, where individuals are studied epidemio­
logically, the current bioinformatics analyses 
lack power and require pooling of subjects to 
detect trends, losing variability estimation in 
the process. In such cases, there will be a need 
to couple default descriptions of PD variabil­
ity with PBPK modeling to obtain an overall 
prediction of variability. In the future, new 
hypothesis­based molecular clinical and epide­
miological approaches that integrate emerging 
biological knowledge of pathways with obser­
vations of physiological disease status, mark­
ers of early biological response, and genetics 
are likely to provide the way forward with 
 population­based descriptions of variability.
Conclusions
Emerging data streams can inform multiple 
aspects of biological variability, be used in 
different modeling approaches addressing 
PK and/or PD variability, and have applica­
tion across different chemi cal screening and 
evaluation schemes. Successful examples of 
addressing PK variability include the devel­
opment and application of a Bayesian PBPK 
model–based analysis syste matically estimat­
ing model parame ters and characterizing their 
uncertainty and variability for TCE, a chemi­
cal with complex toxicokinetics (Chiu et al. 
2009). Additionally, data from animal models 
and large­scale in vitro screening platforms 
that have incorporated population­ based 
genetic determinants (reviewed by Rusyn et al. 
2010), have provided insight into the extent 
of genetic variability in response to a diversity 
of toxicants, as well as aided in the identi­
fication of genetic susceptibility factors that 
underscore the development of toxic pheno­
types. Hypothesis­based molecular clinical 
and epidemiological approaches to integrating 
genetics, molecular pathway data, and clini­
cal observations and biomarkers are likely to 
contribute to population­based descriptions 
of variability. Complementary to these are 
genome­wide (Hutter et al. 2012) and expo­
sure­wide (Patel et al. 2010) approaches for 
assessing human population variability in toxic 
response. Opportunities exist to employ these 
emerging data streams in the development of 
in silico predictive models for application in a 
range of decision­making contexts.
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